Medical weight loss with GLP-1
Semaglutide. A once weekly, provider directed injection targeting the GLP-1 receptor pathway for appetite regulation and weight goals.
What to expect
Our medically supervised weight management program may include medication that acts on the GLP-1 receptor pathway when clinically appropriate. This pathway is involved in appetite, digestion, and glucose dependent insulin signaling. Medication is used alongside nutrition, activity, body composition tracking, and ongoing clinical monitoring.
- Activates the GLP-1 receptor, which can slow stomach emptying and increase feelings of fullness
- Can reduce appetite and food intake while supporting glucose dependent insulin signaling
- Given as a once weekly injection with gradual dose changes directed by your prescriber
- Ask your provider whether SECA body composition scans are included in your plan
- Prescribed by the medical team after your consultation, with ongoing follow up
Provider note: Pricing varies by prescribed dose and formulation. Final eligibility, medication selection, dose, availability, and pricing are confirmed after medical evaluation. A consultation does not guarantee a prescription.
Can be paid monthly. Price depends on the prescribed dose. Office and telehealth visits are $100.
See every dose and monthly price
Single vs dual: GLP-1 and GLP-1/GIP compared
Both are once weekly injections that work with your body hunger hormones. The difference is how many pathways they act on, and how much weight came off in the trials. Here is an honest side by side.
| Option | What it means |
|---|---|
| How it works | GLP-1 alone mimics one gut hormone: it signals fullness to the brain, slows stomach emptying, and releases insulin when blood sugar is high. The dual option adds the GIP pathway on top of that. |
| Appetite and blood sugar | A single pathway quiets appetite, steadies blood sugar, and lowers A1C. In head to head data, the dual option tends to run somewhat stronger on both. |
| Typical results in trials | About 15% average body weight loss at 68 weeks on the top semaglutide dose (STEP 1). Tirzepatide averaged roughly 15 to 21% across doses at 72 weeks (SURMOUNT-1). |
| Head to head | In SURMOUNT-5, tirzepatide averaged 20.2% versus 13.7% for semaglutide at 72 weeks. These are averages, not promises. |
| Common side effects | Mostly gastrointestinal: nausea, constipation, diarrhea, and reflux. Usually mild and most common while the dose is increasing. |
| Who it is for | A well studied, strong first choice, and a good starting point if you want the longest track record or cost favors it. |
Provider note: Neither option is automatically better. Medical history, prior response, side effects, availability, and goals determine the appropriate path.
What we go over together
- These programs require a consultation and are not appropriate for everyone
- Nausea, constipation, diarrhea, abdominal discomfort, bloating, headache, fatigue, or injection site irritation can occur
- Tell the medical team about pregnancy or breastfeeding, pancreatitis, gallbladder disease, severe stomach emptying problems, or diabetes medications
- Tell us about any personal or family history of medullary thyroid carcinoma or MEN2
- Seek urgent care for severe or persistent abdominal pain, severe dehydration, or signs of an allergic reaction
What a listing means
This information is educational and does not establish that a medication treats, cures, or prevents a disease. Availability depends on clinical appropriateness and provider judgment, and a consultation does not guarantee a prescription.
Your prescription, delivered to your door
When medication is prescribed, it is prepared and dispensed by a state licensed Texas pharmacy that compounds patient specific prescriptions under Section 503A, with both sterile and non sterile compounding services.
Your medication ships directly from the pharmacy to your door. Shipping is included, and orders typically arrive within 3 to 5 business days after pharmacy processing.
Patient specific care under Section 503A
Federal law permits qualifying state licensed pharmacies to prepare medication for an individually identified patient pursuant to a valid prescription when Section 503A requirements are met. These patient specific medications do not go through the FDA premarket approval process used for commercially manufactured drugs. Instead, the pharmacy operates under state pharmacy oversight and applicable federal compounding requirements.
Your provider determines whether a compounded formulation is clinically appropriate after looking at your medical history, available treatments, expected benefits, potential risks, and alternatives.
What this page is based on
- Wilding JPH, et al. Once Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. Mean body weight change of -14.9% with semaglutide 2.4 mg versus -2.4% with placebo at 68 weeks.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. Mean weight change of -15.0%, -19.5%, and -20.9% at the 5, 10, and 15 mg doses versus -3.1% placebo at 72 weeks.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. Tirzepatide -20.2% versus semaglutide -13.7% mean weight change at 72 weeks.
Questions, answered
How does GLP-1 help with weight loss?
GLP-1 is a hormone your gut releases after you eat, and the medication is a longer lasting version of it. It tells your brain you are full, slows how fast your stomach empties, and steadies blood sugar, so you get fewer cravings and hunger swings and naturally eat less. In the STEP 1 trial, adults on once weekly semaglutide lost about 15% of their body weight over 68 weeks, versus about 2% on placebo.
Is this the same as Ozempic or Wegovy?
It is the same active medication. Ozempic and Wegovy are brand names for semaglutide, Ozempic approved for type 2 diabetes and Wegovy for weight loss, at different doses. Our program uses a semaglutide class GLP-1, prescribed and dosed for weight loss after a clinical evaluation. The mechanism is identical; the difference is branding, dosing, and how it is prescribed and managed.
What are the side effects?
The most common are gastrointestinal: nausea, constipation, diarrhea, and occasional reflux or vomiting. They are usually mild to moderate, show up most while the dose is increasing, and ease as your body adjusts. Rarer but more serious risks include gallbladder problems and pancreatitis, and it is not used if you have a personal or family history of medullary thyroid cancer or MEN2. We start low, go slow, and adjust the dose to keep side effects manageable.
GLP-1 or GLP-1/GIP, which is right for me?
Both curb appetite and steady blood sugar. The dual GLP-1/GIP option adds a second hormone pathway and produced more weight loss in trials, including a head to head study at about 20% versus 14% at 72 weeks. A single GLP-1 has the longest track record and is a strong choice for most people, especially as a starting point. The right one depends on your weight loss target, medical history, tolerance, and cost, and that is what the consultation sorts out.
Who is a candidate?
These are prescription medications for adults, generally those with a BMI of 30 or higher, or 27 or higher with a weight related condition like high blood pressure, prediabetes, or sleep apnea, the same criteria used in the trials. A provider looks at your health history, current medications, and goals before prescribing, and it is not appropriate during pregnancy or with certain thyroid or pancreatic conditions. The only way to know is a clinical evaluation.
Start with a consult
$100 consultations, same day and next day in most cases.